INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20240269197A1
SERIAL NO

18565038

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure is concerned with a combination comprising at least one butyrate-producing bacterium and at least one insulin-sensitizing agent for use in the prevention and/or treatment of metabolic disease, insulin resistance and insulin resistance-related conditions, preferably chosen from type 1 diabetes mellitus, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, insulin resistance in endocrine disease, Polycystic Ovary Syndrome (PCOS), Nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). The insulin-sensitizing agent and the butyrate-producing bacterium, at least in part, have a synergistic effect on lowering insulin resistance in subjects.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CAELUS PHARMACEUTICALS B V3474 KG ZEGVELD

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bui, Thi Phuong Nam Bennekom, NL 4 0
De, Vos Willem Meindert Amsterdam, NL 38 193
Gul, Ismail Sahin Herentals, BE 1 0
Sterkman, Lucas Gerardus Willibrordus Heiloo, NL 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation